GE HealthCare forecast Intelerad’s revenue to be approximately $270 million in the first full year of ownership. The deal ...

The chief medical officer for the new J&J unit discussed intravascular lithotripsy’s rapid growth and what to expect from the ...

The company has stepped up its interest in M&A since making a $4.1 billion divestiture that strengthened its balance sheet.

The proposed deal, the largest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer testing.

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

Artificial intelligence combines ultrasound and X-ray images to give physicians a real-time 3D view of the repair device ...

By targeting ambulatory surgery centers, the company is gearing up to compete with Intuitive Surgical for an emerging ...

Intended for use in structural heart procedures, the cardiac imaging catheter is expected to drive growth for Boston ...

Pulsed field ablation sales grew by more than 300% in the second quarter for the company’s fiscal year 2026, amid mounting ...

The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and ...

The funding will support reimbursement initiatives and partnerships to make Clairity Breast accessible across community ...